Abstract
References
Sams WM, Lynch PJ. Principles and practice of dermatology. Churchill Livingstone; 1990
Gutman DH. Parallels between tuberous sclerosis complex and neurofibromatosis: common threads in the same tapestry. Semin Paed Neurol 1998;5:276-286. Available from: https://doi.org/10.1016/s1071-9091(98)80006-5
Huson SM. What level of care for the neurofibromatoses? Lancet 1999;353:1114-1116. Available from: https://doi.org/10.1016/S0140-6736(98)00155-X
Korf BR. Plexiform neurofibromas. Am J Med Gen 1999;89:31-37. Available from: https://doi.org/10.1002/(sici)1096-8628(19990326)89:1<31::aid-ajmg7>3.0.co;2-w
Ahn MS, Robert K, Jackler MB, Lawrence R, Lustig MD. The early history of the neurofibromatosis. Evolution of the concept of neurofibromatosis type 2 . Arch Otolaryngol Head Neck Surg 1996; 122:1240-1249. Available from: https://doi.org/10.1001/archotol.1996.01890230086016
Pembrey ME. Genetic factors in disease. In Oxford Textbook of Medicine. 3rd ed. Oxford University Press; 1996 pp100-138.
Weiss B, Bollag G, Shannon K. Hyperactive Ras as a therapeutic target in neurofibromatosis type 1. Am J Med Gen 1999;89:14-22
Harvey JJ, East J. The murine sarcoma virus. lnt Rev Exp Path 1971;10:265-360
Harnden DG, Carcinogene IS. In: McGee JO'D, Isaacson PG, Wright NA (eds). Oxford Textbook of Pathology, Oxford University Press; 1992:pp633-678
Lu X, Horvitz HR. lin-35 and lin-53, two genes that antagonize a C. elegans Ras pathway, encode proteins similar to Rb and its binding protein RbAp48. Cell 1998;95:981-991. Available from: https://doi.org/10.1016/s0092-8674(00)81722-5
Burck KB, Lui ET, Larrick JW. Oncogene. Springer Verlag;1988
Feldkamp MM, Angelov L, Guba A. Neurofibromatosis type l peripheral nerve tumours: aberrant activation of the Ras pathway. Surg Neurol 1999;51:211-218. Available from: https://doi.org/10.1016/s0090-3019(97)00356-x
Blewitt RW. Update on lymphoma pathology II: the role of genetic mutations in the pathogenesis of lymphoid neoplasia Lancaster and Westmorland Medical Journal 1998;3(3):102-105. Available from: https://doi.org/10.48037/mbmj.v3i3.553
Kerkhoff E, Rapp UR. Cell target of Ras/Raf signalling. Oncogene 1998:17:1457-1462. Available from: https://doi.org/10.1038/sj.onc.1202185
Bos JL. Ras oncogenes in human cancer: a review . Cancer Res 1989;49:4682-4689
Weitzman JB, Yaniv M. Rebuilding the road to cancer. Nature 1999;400:401-402. Available from: https://doi.org/10.1038/22637
Serra E, Puig S, Otero D, et al. Confirmation of a double-hit model for the NFJ gene in benign neurofibromas. Am J Hum Genet 1997;61:512-519. Available from: https://doi.org/10.1086/515504
Sawada S, Florell S, Purandare SM, et al. Identification of NF1 mutations in both alleles of a dermal neurofibroma. Nat Genet. 1996 Sep;14(1):110-2. Available from: https://doi.org/10.1038/ng0996-110
Loeb LA. Mutator phenotype may be required for multistage carcinogenesis. Cancer Res 1991;51(12):3075-3079.
Walton RG, Jacobs AH, Cox AJ. Pigmented lesions in newborn infants. Br J Dermatol 1976;95(4):389-96. Available from: https://doi.org/10.1111/j.1365-2133.1976.tb00840.x
Rook A, Wilkinson OS, Ebling FJG, et al. Textbook of dermatology. 4th ed. Blackwell; 1986
Burton JL. Essentials of dermatology. 3rd ed. Churchill Livingstone; 1990
Murphy M, Bartlett PF. Molecular regulation of neural crest development. Mol Neurobiol 1993;7:111-135. Available from: https://doi.org/10.1007/BF02935639
Kincannon J, Boutzale C. The physiology of pigmented nevi. Pediatrics 1999;104:1042-1045
Lambert J, Vancoille G, Naeyaert JM. Molecular motors and their role in pigmentation. Cell Mol Biol 1999;45:905-918
Rosdahl I, Rorsman H. An estimate of the melanocyte mass in humans. J Invest Dermatol 1983;81:278-281. Available from: https://doi.org/10.1111/1523-1747.ep12518318
Moschella and Hurley. Dermatology. 3rd ed. Saunders; 1992
Morris JA. Spontaneous mutation rate in retinoblastoma. J Clin Pathol 1990;43:496-498. Available from: https://doi.org/10.1136/jcp.43.6.496
Boyer JC, Farber RA. Mutation rate of a microsatellite sequence in normal human fibroblast . Cancer Res J 998;58:3946-3949
Morris JA. Stem cell kinetics and intestinal cancer. Anticancer Res 1994;14:2073-2076
British National Formulary 2000;39: 11 Prescribing for children
Baird EA, McHenry DM, MacKie RM. Effect of maintenance chemotherapy in childhood on numbers of melanocytic naevi. BMJ 1992;305:799-801. Available from: https://doi.org/10.1136/bmj.305.6857.799
Wang X, Thant AA, Machida K, et al. Suppression of cell growth by ectopic expression of N-cadherin. Int J Oncol 1998;12:1097-1101. Available from: https://doi.org/10.3892/ijo.12.5.1097
Kang J, Krauss RS. Ras induces anchorage-independent growth by subverting multiple adhesion regulated cell cycle events. Mol Cell Biol 1996;16:3370-3380. Available from: https://doi.org/10.1128/MCB.16.7.3370
Papp T, Pemsel H, Zimmermann R, et al. Mutational analysis of the N-ras, p53, p16INK4a, CDK4, and MC1R genes in human congenital melanocytic naevi. J Med Genet 1999;36:610-614